Randomized Phase III Trial Comparing an Association of Hormonal Treatment and Docetaxel Versus the Hormonal Treatment Alone in Metastatic Prostate Cancers.

Trial Profile

Randomized Phase III Trial Comparing an Association of Hormonal Treatment and Docetaxel Versus the Hormonal Treatment Alone in Metastatic Prostate Cancers.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Docetaxel (Primary) ; Antiandrogens; Goserelin
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Acronyms GETUG-15
  • Most Recent Events

    • 18 Feb 2017 Results of early benefit data of docetaxel from two studies (GETUG-AFU15 and CHAARTED) presented at the 2017 Genitourinary Cancers Symposium
    • 07 Jan 2013 Primary endpoint 'Overall-survival-rate' has not been met.
    • 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top